Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Protara TherapeuticsTARA -1.78%34 Cyclically Adjusted PB Ratio is 0.20 as of Sep. 16, 2026. GuruFocus rates TARA with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 680 Biotechnology companies, Protara Therapeutics ranks worse than 147058.68% on this metric.
Protara Therapeutics (NAS:TARA) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Protara Therapeutics Cyclically Adjusted PB Ratio Related Terms
Protara Therapeutics Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Protara Therapeutics's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protara Therapeutics Cyclically Adjusted PB Ratio Chart
TARA vs SLGL, GLSI, NERV: Cyclically Adjusted PB Ratio Comparison
For the Biotechnology subindustry, Protara Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protara Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protara Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Protara Therapeutics's Cyclically Adjusted PB Ratio falls into.
Protara Therapeutics Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Protara Therapeutics does not have a history long enough to calculate Cyclically Adjusted Book per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PB Ratio for this company.
What does a Cyclically Adjusted PB Ratio of 0.20 mean?
Protara Therapeutics (TARA) has a Cyclically Adjusted PB Ratio of 0.20 as of Sep. 16, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Protara Therapeutics and its competitors. According to the industry distribution chart, Protara Therapeutics ranks #999999 out of 680 companies in the Biotechnology industry.
Is Protara Therapeutics' Cyclically Adjusted PB Ratio too high?
Protara Therapeutics' current Cyclically Adjusted PB Ratio is 0.20. The Biotechnology industry median Cyclically Adjusted PB Ratio is 1.58. Protara Therapeutics' value of 0.20 is 87.3% below this industry median. Based on the distribution chart, Protara Therapeutics ranks #999999 out of 680 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Protara Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Protara Therapeutics' Cyclically Adjusted PB Ratio compare to SLGL and GLSI?
According to the Biotechnology industry distribution chart, Protara Therapeutics ranks #999999 out of 680 companies for Cyclically Adjusted PB Ratio. This places Protara Therapeutics in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.58. Protara Therapeutics' value of 0.20 is 87.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Biotechnology company?
The median Cyclically Adjusted PB Ratio among Biotechnology companies is 1.58, based on 680 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Protara Therapeutics's current Cyclically Adjusted PB Ratio of 0.20 is 87.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Protara Therapeutics and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PB Ratio is 1.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Protara Therapeutics's current Cyclically Adjusted PB Ratio is 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protara Therapeutics stock overvalued right now?
Protara Therapeutics (TARA) has a current Cyclically Adjusted PB Ratio of 0.20. The current Cyclically Adjusted PB Ratio is 0.20 and 87.3% below the Biotechnology industry median of 1.58. Protara Therapeutics' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Protara Therapeutics (TARA), the current Cyclically Adjusted PB Ratio is 0.20 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
34GF Score
Get the complete analysis for TARA
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TARA has been successfully added to your 
